Leading Developer of Multi-Layer Oral Thin Film Completes Going Public Transaction
CURE Pharmaceutical, a pre-eminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, recently announced the completion of a going public transaction and the issuance of its new stock symbol – CURR.
“After nearly 6 years of intense R&D activities, CURE Pharmaceutical is pleased to finally become a publicly traded entity, and anticipates a series of exciting business development announcements in the months to come,” said Rob Davidson, CEO of CURE Pharmaceutical.
Headquartered in Oxnard, CA, CURE Pharmaceutical has developed and manufactures the most advanced oral thin film (CureFilm™) on the market today supported by its in-house, industry-leading full-service cGMP manufacturing facility. CureFilm is more stable and durable than other oral thin films, with the ability to augment the dissolution for the intended rate of release through the buccal or gastrointestinal system. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance, through its patented application of creating multiple layers, and sub-encapsulation of the delivered compound, potentially improving onset of action, lowering dosing, and enhancing, efficacy, thereby widening the therapeutic index.
CURE Pharmaceutical is now traded under the symbol CURR. For more information about CURE Pharmaceutical, visit www.curepharmaceutical.com.
Contact:
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
Total Page Views: 991
